Detection and identification of ACP-105 and its metabolites in equine urine using LC/MS/MS after oral administration.
ACP-105
SARMs
doping
mass spectrometry
metabolite characterization
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
27
01
2020
revised:
27
07
2020
accepted:
17
08
2020
pubmed:
28
8
2020
medline:
25
2
2023
entrez:
28
8
2020
Statut:
ppublish
Résumé
ACP-105 is a novel nonsteroidal selective androgen receptor modulator (SARM) with a tissue-specific agonist effect and does not have side effects associated with the use of common androgens. This research reports a comprehensive study for the detection of ACP-105 and its metabolites in racehorses after oral administration (in vivo) and postulating its structures using mass spectrometric techniques. To obtain the metabolic profile of ACP-105, a selective and reliable LC-MS/MS method was developed. The chemical structures of the metabolites were determined based on their fragmentation pattern, accurate mass, and retention time. Under the current experimental condition, a total of 19 metabolites were detected in ACP-105 drug administered equine urine samples. The study results suggest the following: (1) ACP-105 is prone to oxidation, which gives corresponding monohydroxylated, dihydroxylated, and trihydroxylated metabolites; (2) along with oxidation, there is a possibility of elimination of water molecule (dehydration) from the third position of the tropine moiety, resulting in the dehydrated analogs of corresponding monohydroxylated, dihydroxylated, and trihydroxylated metabolites; (3) from the study on the metabolites using LC-MS/MS, it is clear that the fragmentation pattern is identical and a great number of fragment ions are common in all the metabolites and the parent drug. (4) The ACP-105 and its metabolites were detected for up to 72 h; thus, the result is a valuable tool for evaluating its use and/or misuse in sport.
Substances chimiques
2-chloro-4-(3-hydroxy-3-methyl-8-azabicyclo(3.2.1)oct-8-yl)-3-methylbenzonitrile
0
Androgens
0
Azabicyclo Compounds
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
299-317Informations de copyright
© 2020 John Wiley & Sons, Ltd.
Références
Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev. 1987;8(1):1-28.
Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell. 1995;83(6):835-839.
Sar M, Lubahn DB, French FS, Wilson EM. Immuno-histochemical localization of the androgen receptor in rat and human tissues. Endocrinology. 1990;127(6):3180-3186.
Gao W, Bohl CE, Dalton JT. Chemistry and structural biology of androgen receptor. Chem Rev. 2005;105(9):3352-3370.
Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25(2):276-308.
Mohler ML, Bohl CE, Jones A, et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem. 2009;52(12):3597-3617.
Acevedo S, Gardell L, Bradley SR, Piu F, Raber J. Selective androgens receptor modulators antagonize apolipoprotein E4-induced cognitive impairments. Lett Drug des Discovery. 2008;5(4):271-276.
Rosen J, Negro-Vilar A. Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J Musculoskelet Neuronal Interact. 2002;2:222-224.
Yarrow JF, Conover CF, McCoy SC, et al. 17-Hydroxyestra- 4, 9, 11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate. Am J Physiol Endocrinol Metab. 2011;300(4):E650-E660.
Haendler B, Cleve A. Recent developments in antiandrogens and selective androgen receptor modulators. Mol Cell Endocrinol. 2012;352(1-2):79-91.
Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008;6:1-26, E010.
Allan G, Lai M, Sbriscia T, et al. A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats. J Steroid Biochem Mol Biol. 2007;103(1):76-83.
Gao W, Reiser P, Coss C, et al. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology. 2005;146(11):4887-4897.
Sun C, Robl J, Wang T, et al. Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold. J Med Chem. 2006;49(26):7596-7599.
Schlienger N, Lund BW, Pawlas J, et al. Synthesis, structure-activity relationships, and characterization of novel non-steroidal and selective androgen receptor modulators. J Med Chem. 2009;52(22):7186-7191.
Grata E, Perrenoud L, Saugy M, Baume N. SARM-S4 and metabolites detection in sports drug testing: a case report. Forensic Sci Int. 2011;213(1-3):104-108.
Starcevic B, Ahrens BD, Butch AW. Detection of the selective androgen receptor modulator S-4 (andarine) in a doping control sample. Drug Test Anal. 2013;5(5):377-379.
Kintz P, Ameline A, Gheddar L, Raul J. LGD-4033, S-4 and MK-2866-testing for SARMs in hair: about 2 doping cases. Toxicologie Analy & Cliniq. 2019;31(1):56-63.
Beuck S, Schänzer W, Thevis M. Investigation of the in vitro metabolism of the emerging drug candidate S107 for doping-preventive purposes. J Mass Spectrom. 2011;46(2):112-130.
Thevis M, Geyer H, Thomas A, Schänzer W. Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet. Drug Test Anal. 2011;3(5):331-336.
Thevis M, Thomas A, Piper T, Krug O, Delahaut P, Schänzer W. Liquid chromatography-high resolution/high accuracy (tandem) mass spectrometry based identification of in vivo generated metabolites of the selective androgen receptor modulator ACP-105 for doping control purposes. Eur J Mass Spectrom. 2014;20(1):73-83.
Thevis M, Piper T, Beuck S, Geyer H, Schänzer W. Expanding sports drug testing assays: Mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105. Rapid Commun Mass Spectrom. 2013;27(11):1173-1182.
Subhahar M, Singh J, Albert PH, Kadry AM. Pharmacokinetics, metabolism and excretion of celecoxib, a selective cyclooxygenase- 2 inhibitor, in horse. J Vet Pharmacol Therap. 2019;1-7.